American Society of Clinical Oncology Annual Meeting 2025
Target Audience: oncologists, hematologists, pathologists, radiologists, surgical, and radiation oncologists Information: The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago, Illinois, under the theme “Driving Knowledge to Action: Building a Better Future”. Here are some key highlights:- Over 5,400 presentations covered cutting-edge research, clinical trials, and treatment innovations across a wide range of cancers.
- Breast, lung, ovarian, and colorectal cancers were among the most featured tumor types.
- AstraZeneca and Daiichi Sankyo presented promising results from the DESTINY-Breast09 study, suggesting a potential new standard of care for HER2-positive metastatic breast cancer.
- Gilead and Merck & Co made headlines with their TROP-2–targeted therapy Trodelvy combined with Keytruda, showing strong results in triple-negative breast cancer.
- Amgen’s Imdelltra showed significant benefit in small cell lung cancer, a notoriously tough-to-treat disease.
- In ovarian cancer, the ROSELLA trial and OVATION-2 study offered encouraging data for patients with resistant or advanced disease
- Medical, surgical, and radiation oncologists
- Hematologists, pathologists, and radiologists
- Primary care physicians and internal medicine specialists
- Gynecologic, thoracic, colorectal, and urologic surgeons
- Pulmonologists, dermatologists, and oral surgeons
- Oncology nurse practitioners, nurses, and physician assistants
- Residents, fellows, and medical students
- Allied health professionals involved in oncology care and research
